The SPEAC Project has released an updated list of Adverse Events of Special Interest (AESI) for Rift Valley fever (RVF) vaccines. This update reflects the latest evidence from vaccine development efforts, disease pathogenesis research, and emerging safety data from peer-reviewed and gray literature sources.
As with all SPEAC AESI lists, this update is grounded in three primary criteria:
- Known association with immunization or a specific vaccine platform
- Occurrence during wild-type disease due to viral replication and/or immunopathogenesis
- Theoretical association supported by mechanistic insights or animal models
This revision incorporates new scientific findings relevant to RVF vaccine platforms currently in development, including considerations for special populations such as pregnant women, children, and immunocompromised individuals.
The updated AESI list supports vaccine developers, regulators, and public health stakeholders in harmonizing safety monitoring efforts to improve comparability across trials and accelerate preparedness for potential outbreaks across clinical trials. This update was expedited to support the design of possible clinical trials of investigational RVF vaccines during the current outbreak in Senegal and Mauritania and future outbreaks.
The FAO/WHO/WOAH recently released a rapid risk assessment that captures the risk to affected countries, region and world, which can be accessed HEREĀ
The SPEAC Executive Board welcomes continued input on this AESI list and will further revise it as new data emerge. Feedback may be shared with the SPEAC and Brighton Collaboration team at bc-coordinator@taskforce.org.
š Access the updated Rift Valley fever AESI list here:
https://speacsafety.net/tools/aesi-lists/rift-valley-fever/
